Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma
NCT04277845 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49
Last updated 2022-09-09
Summary
To compare the efficacy and safety of bortezomib, lenalidomide and dexamethasone in elderly frail patients with newly diagnosed multiple myeloma.
Conditions
Interventions
- DRUG
-
Bortezomib, Lenalidomide, Dexamethasone
Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
Sponsors & Collaborators
-
Samsung Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-08-06
- Primary Completion
- 2022-03-23
- Completion
- 2025-03-31
Countries
- South Korea
Study Locations
More Related Trials
-
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT02375555 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
NCT02441686 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
NCT01782963 ·Status: COMPLETED ·Phase: PHASE2
-
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT04151667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
NCT01647165 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209 ·Status: COMPLETED ·Phase: PHASE2
-
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
NCT05665140 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
NCT04052880 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
NCT02874742 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01863550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
NCT02082405 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
NCT01217957 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
NCT03669445 ·Status: UNKNOWN ·Phase: PHASE2
-
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
NCT02474563 ·Status: COMPLETED
-
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
NCT03673826 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
NCT07206810 ·Status: COMPLETED
-
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
NCT01954784 ·Status: TERMINATED ·Phase: PHASE1
-
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
NCT05497102 ·Status: RECRUITING ·Phase: PHASE2
-
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387 ·Status: RECRUITING ·Phase: PHASE3
-
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
NCT03487133 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
NCT01645930 ·Status: COMPLETED ·Phase: PHASE1